Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

August 31, 1998

Primary Completion Date

January 31, 2001

Study Completion Date

January 31, 2001

Conditions
Graft Versus Host DiseaseLeukemiaMyelodysplastic SyndromesThymic Carcinoma
Interventions
BIOLOGICAL

anti-thymocyte globulin

DRUG

busulfan

DRUG

cyclophosphamide

DRUG

cyclosporine

DRUG

melphalan

DRUG

methylprednisolone

PROCEDURE

umbilical cord blood transplantation

RADIATION

radiation therapy

Trial Locations (15)

10021

New York Blood Center, New York

27710

Duke Comprehensive Cancer Center, Durham

29203

University of South Carolina School of Medicine, Columbia

32207

Division of Pediatric Surgery, Jacksonville

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

60612

Rush-Presbyterian-St. Luke's Medical Center, Chicago

60637

University of Chicago Cancer Research Center, Chicago

63104

Cardinal Glennon Children's Hospital, St Louis

70118

Children's Hospital of New Orleans, New Orleans

32610-0296

University of Florida Health Science Center, Gainesville

07601

Hackensack University Medical Center, Hackensack

14263-0001

Roswell Park Cancer Institute, Buffalo

27599-7295

Lineberger Comprehensive Cancer Center, UNC, Chapel Hill

19134-1095

St. Christopher's Hospital for Children, Philadelphia

29425-0721

Medical University of South Carolina, Charleston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Roswell Park Cancer Institute

OTHER

NCT00003662 - Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases | Biotech Hunter | Biotech Hunter